PURPOSE: This study was designed to provide a comprehensive assessment on the role of beta1,6-branched oligosaccharides in the metastasis and outcome of breast carcinoma. Generation of these structures on N-glycans is initiated by beta1,6-N-acetylglucosaminyltransferase V and used by both myeloid cells and cancer cells in systemic migration. EXPERIMENTAL DESIGN: Tissue microarrays of >700 tumors (>400 patients; 30-year follow-up data) were stained through lectin histochemistry with leukocytic phytohemagglutinin (LPHA), a selective marker for beta1,6-branched oligosaccharides. Node-negative and node-positive primary tumors and patient-matched lymph node metastases were scored by blinded observers. RESULTS: Metastases stained at significantly greater intensities than did the patient-matched primary tumors (P < 0.0001), demonstrating for the first time that the abundance of beta1,6-branched oligosaccharides was directly associated with breast carcinoma nodal metastasis. Multivariate analyses revealed that beta1,6-branched oligosaccharides in primary tumors were a predictor of poor outcome, most notably in node-negative tumors, where an LPHA staining score of 3+ gave a risk factor of 3.3, independent of tumor size, nuclear grade, or patient age (P = 0.007). CONCLUSIONS: The data firmly establish a role for beta1,6-N-acetylglucosaminyltransferase V activity and beta1,6-branched oligosaccharides in breast carcinoma metastasis, and reemphasize the involvement, although poorly understood, of aberrant glycosylation in tumor progression.
No takes yet. Share an insight, caveat, or question.
Handerson et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: